Differential neutralizing antibody responses elicited by CoronaVac and BNT162b2 against SARS-CoV-2 Lambda in Chile
SARS-CoV-2 variant Lambda was dominant in several South American countries, including Chile. To ascertain the efficacy of local vaccination efforts, we used pseudotyped viruses to characterize the neutralization capacity of antibodies elicited by CoronaVac ( n = 53) and BNT162b2 ( n = 56) in healt...
Gespeichert in:
| Veröffentlicht in: | Nature microbiology 2022-04, Vol.7 (4), p.524-529 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 529 |
|---|---|
| container_issue | 4 |
| container_start_page | 524 |
| container_title | Nature microbiology |
| container_volume | 7 |
| creator | Acevedo, Mónica L. Gaete-Argel, Aracelly Alonso-Palomares, Luis de Oca, Marco Montes Bustamante, Andrés Gaggero, Aldo Paredes, Fabio Cortes, Claudia P. Pantano, Sergio Martínez-Valdebenito, Constanza Angulo, Jenniffer Le Corre, Nicole Ferrés, Marcela Navarrete, Marcelo A. Valiente-Echeverría, Fernando Soto-Rifo, Ricardo |
| description | SARS-CoV-2 variant Lambda was dominant in several South American countries, including Chile. To ascertain the efficacy of local vaccination efforts, we used pseudotyped viruses to characterize the neutralization capacity of antibodies elicited by CoronaVac (
n
= 53) and BNT162b2 (
n
= 56) in healthcare workers from Clínica Santa María and the Faculty of Medicine at Universidad de Chile, as well as in convalescent plasma from individuals infected during the first wave visiting the Hospital Clínico at Pontificia Universidad Católica (
n
= 30). We observed that BNT162b2 elicits higher neutralizing antibody titres than CoronaVac, with differences ranging from 7.4-fold for the ancestral spike (Wuhan-Hu-1) to 8.2-fold for the Lambda spike and 13-fold for the Delta spike. Compared with the ancestral virus, neutralization against D614G, Alpha, Gamma, Lambda and Delta variants was reduced by between 0.93- and 4.22-fold for CoronaVac, 1.04- and 2.38-fold for BNT162b2, and 1.26- and 2.67-fold for convalescent plasma. Comparative analyses among the spike structures of the different variants suggest that mutations in the spike protein from the Lambda variant, including the 246–252 deletion in an antigenic supersite at the N-terminal domain loop and L452Q/F490S within the receptor-binding domain, may account for immune escape. Interestingly, analyses using pseudotyped and whole viruses showed increased entry rates into HEK293T-ACE2 cells, but reduced replication rates in Vero-E6 cells for the Lambda variant when compared with the Alpha, Gamma and Delta variants. Our data show that inactivated virus and messenger RNA vaccines elicit different levels of neutralizing antibodies with different potency to neutralize SARS-CoV-2 variants, including the variant of interest Lambda.
The SARS-CoV-2 Lambda variant has been prevalent in Latin America. An analysis of the neutralization capacity of antibodies elicited by CoronaVac and BNT162b2 against SARS-CoV-2 Lambda in plasma from healthcare workers and patients in Chile reveals that BNT162b2 elicits higher neutralizing antibody titres than CoronaVac. |
| doi_str_mv | 10.1038/s41564-022-01092-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2646724891</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2646027749</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-59224a002ebdbddf4361578c839701589278628ada6ff4475c62d4a8edb7d2b3</originalsourceid><addsrcrecordid>eNp9kU1vFCEYgInR2Kb2D3gwJF68UOEdBphjndpqsqmJ3fRKYGBWmllYYeaw_vrSbv2Ih54g8PDwJg9Cbxk9Y7RRHwtnreCEAhDKaAeEvUDHQFtFWpDi5T_7I3Rayh2llAkQQonX6KhpG9FKJY9Rvgjj6LOPczATjn6Zs5nCrxA32NQzm9weZ192KRZfsJ_CEGbvsN3jPuUUza0ZKujwp-t11VvAZmNCLDO-Of9-Q_p0SwCvzNY6g0PE_Y8w-Tfo1Wim4k-f1hO0vvy87r-Q1berr_35igycdTNpOwBuKAVvnXVu5I1gdeZBNZ2krFUdSCVAGWfEOHIu20GA40Z5Z6UD25ygDwftLqefiy-z3oYy-Gky0aelaBBcSOCqYxV9_x96l5Yc63CPFAUpeVcpOFBDTqVkP-pdDluT95pR_dBEH5ro2kQ_NtEP6ndP6sVuvfvz5HeBCjQHoNSruPH579_PaO8BiLeU3Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2646027749</pqid></control><display><type>article</type><title>Differential neutralizing antibody responses elicited by CoronaVac and BNT162b2 against SARS-CoV-2 Lambda in Chile</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Acevedo, Mónica L. ; Gaete-Argel, Aracelly ; Alonso-Palomares, Luis ; de Oca, Marco Montes ; Bustamante, Andrés ; Gaggero, Aldo ; Paredes, Fabio ; Cortes, Claudia P. ; Pantano, Sergio ; Martínez-Valdebenito, Constanza ; Angulo, Jenniffer ; Le Corre, Nicole ; Ferrés, Marcela ; Navarrete, Marcelo A. ; Valiente-Echeverría, Fernando ; Soto-Rifo, Ricardo</creator><creatorcontrib>Acevedo, Mónica L. ; Gaete-Argel, Aracelly ; Alonso-Palomares, Luis ; de Oca, Marco Montes ; Bustamante, Andrés ; Gaggero, Aldo ; Paredes, Fabio ; Cortes, Claudia P. ; Pantano, Sergio ; Martínez-Valdebenito, Constanza ; Angulo, Jenniffer ; Le Corre, Nicole ; Ferrés, Marcela ; Navarrete, Marcelo A. ; Valiente-Echeverría, Fernando ; Soto-Rifo, Ricardo</creatorcontrib><description>SARS-CoV-2 variant Lambda was dominant in several South American countries, including Chile. To ascertain the efficacy of local vaccination efforts, we used pseudotyped viruses to characterize the neutralization capacity of antibodies elicited by CoronaVac (
n
= 53) and BNT162b2 (
n
= 56) in healthcare workers from Clínica Santa María and the Faculty of Medicine at Universidad de Chile, as well as in convalescent plasma from individuals infected during the first wave visiting the Hospital Clínico at Pontificia Universidad Católica (
n
= 30). We observed that BNT162b2 elicits higher neutralizing antibody titres than CoronaVac, with differences ranging from 7.4-fold for the ancestral spike (Wuhan-Hu-1) to 8.2-fold for the Lambda spike and 13-fold for the Delta spike. Compared with the ancestral virus, neutralization against D614G, Alpha, Gamma, Lambda and Delta variants was reduced by between 0.93- and 4.22-fold for CoronaVac, 1.04- and 2.38-fold for BNT162b2, and 1.26- and 2.67-fold for convalescent plasma. Comparative analyses among the spike structures of the different variants suggest that mutations in the spike protein from the Lambda variant, including the 246–252 deletion in an antigenic supersite at the N-terminal domain loop and L452Q/F490S within the receptor-binding domain, may account for immune escape. Interestingly, analyses using pseudotyped and whole viruses showed increased entry rates into HEK293T-ACE2 cells, but reduced replication rates in Vero-E6 cells for the Lambda variant when compared with the Alpha, Gamma and Delta variants. Our data show that inactivated virus and messenger RNA vaccines elicit different levels of neutralizing antibodies with different potency to neutralize SARS-CoV-2 variants, including the variant of interest Lambda.
The SARS-CoV-2 Lambda variant has been prevalent in Latin America. An analysis of the neutralization capacity of antibodies elicited by CoronaVac and BNT162b2 against SARS-CoV-2 Lambda in plasma from healthcare workers and patients in Chile reveals that BNT162b2 elicits higher neutralizing antibody titres than CoronaVac.</description><identifier>ISSN: 2058-5276</identifier><identifier>EISSN: 2058-5276</identifier><identifier>DOI: 10.1038/s41564-022-01092-1</identifier><identifier>PMID: 35365787</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>13/1 ; 13/109 ; 38/22 ; 38/5 ; 631/326/596/4130 ; 692/699/255/2514 ; ACE2 ; Angiotensin-converting enzyme 2 ; Antibodies ; Antibodies, Neutralizing - metabolism ; Biomedical and Life Sciences ; BNT162 Vaccine ; Brief Communication ; Chile ; Comparative analysis ; COVID-19 - therapy ; COVID-19 Serotherapy ; COVID-19 vaccines ; Health care ; HEK293 Cells ; Humans ; Immunization, Passive ; Infectious Diseases ; Life Sciences ; Medical Microbiology ; Medical personnel ; Membrane Glycoproteins - metabolism ; Microbiology ; mRNA ; Parasitology ; RNA viruses ; SARS-CoV-2 - genetics ; Severe acute respiratory syndrome coronavirus 2 ; Spike Glycoprotein, Coronavirus - genetics ; Spike protein ; Viral Envelope Proteins - metabolism ; Virology</subject><ispartof>Nature microbiology, 2022-04, Vol.7 (4), p.524-529</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Limited 2022. corrected publication 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2022. The Author(s), under exclusive licence to Springer Nature Limited.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c419t-59224a002ebdbddf4361578c839701589278628ada6ff4475c62d4a8edb7d2b3</citedby><cites>FETCH-LOGICAL-c419t-59224a002ebdbddf4361578c839701589278628ada6ff4475c62d4a8edb7d2b3</cites><orcidid>0000-0001-9156-2516 ; 0000-0001-6435-4543 ; 0000-0001-9101-9783 ; 0000-0003-0945-2970 ; 0000-0002-2836-9817 ; 0000-0002-2044-9548</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41564-022-01092-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41564-022-01092-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27922,27923,41486,42555,51317</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35365787$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Acevedo, Mónica L.</creatorcontrib><creatorcontrib>Gaete-Argel, Aracelly</creatorcontrib><creatorcontrib>Alonso-Palomares, Luis</creatorcontrib><creatorcontrib>de Oca, Marco Montes</creatorcontrib><creatorcontrib>Bustamante, Andrés</creatorcontrib><creatorcontrib>Gaggero, Aldo</creatorcontrib><creatorcontrib>Paredes, Fabio</creatorcontrib><creatorcontrib>Cortes, Claudia P.</creatorcontrib><creatorcontrib>Pantano, Sergio</creatorcontrib><creatorcontrib>Martínez-Valdebenito, Constanza</creatorcontrib><creatorcontrib>Angulo, Jenniffer</creatorcontrib><creatorcontrib>Le Corre, Nicole</creatorcontrib><creatorcontrib>Ferrés, Marcela</creatorcontrib><creatorcontrib>Navarrete, Marcelo A.</creatorcontrib><creatorcontrib>Valiente-Echeverría, Fernando</creatorcontrib><creatorcontrib>Soto-Rifo, Ricardo</creatorcontrib><title>Differential neutralizing antibody responses elicited by CoronaVac and BNT162b2 against SARS-CoV-2 Lambda in Chile</title><title>Nature microbiology</title><addtitle>Nat Microbiol</addtitle><addtitle>Nat Microbiol</addtitle><description>SARS-CoV-2 variant Lambda was dominant in several South American countries, including Chile. To ascertain the efficacy of local vaccination efforts, we used pseudotyped viruses to characterize the neutralization capacity of antibodies elicited by CoronaVac (
n
= 53) and BNT162b2 (
n
= 56) in healthcare workers from Clínica Santa María and the Faculty of Medicine at Universidad de Chile, as well as in convalescent plasma from individuals infected during the first wave visiting the Hospital Clínico at Pontificia Universidad Católica (
n
= 30). We observed that BNT162b2 elicits higher neutralizing antibody titres than CoronaVac, with differences ranging from 7.4-fold for the ancestral spike (Wuhan-Hu-1) to 8.2-fold for the Lambda spike and 13-fold for the Delta spike. Compared with the ancestral virus, neutralization against D614G, Alpha, Gamma, Lambda and Delta variants was reduced by between 0.93- and 4.22-fold for CoronaVac, 1.04- and 2.38-fold for BNT162b2, and 1.26- and 2.67-fold for convalescent plasma. Comparative analyses among the spike structures of the different variants suggest that mutations in the spike protein from the Lambda variant, including the 246–252 deletion in an antigenic supersite at the N-terminal domain loop and L452Q/F490S within the receptor-binding domain, may account for immune escape. Interestingly, analyses using pseudotyped and whole viruses showed increased entry rates into HEK293T-ACE2 cells, but reduced replication rates in Vero-E6 cells for the Lambda variant when compared with the Alpha, Gamma and Delta variants. Our data show that inactivated virus and messenger RNA vaccines elicit different levels of neutralizing antibodies with different potency to neutralize SARS-CoV-2 variants, including the variant of interest Lambda.
The SARS-CoV-2 Lambda variant has been prevalent in Latin America. An analysis of the neutralization capacity of antibodies elicited by CoronaVac and BNT162b2 against SARS-CoV-2 Lambda in plasma from healthcare workers and patients in Chile reveals that BNT162b2 elicits higher neutralizing antibody titres than CoronaVac.</description><subject>13/1</subject><subject>13/109</subject><subject>38/22</subject><subject>38/5</subject><subject>631/326/596/4130</subject><subject>692/699/255/2514</subject><subject>ACE2</subject><subject>Angiotensin-converting enzyme 2</subject><subject>Antibodies</subject><subject>Antibodies, Neutralizing - metabolism</subject><subject>Biomedical and Life Sciences</subject><subject>BNT162 Vaccine</subject><subject>Brief Communication</subject><subject>Chile</subject><subject>Comparative analysis</subject><subject>COVID-19 - therapy</subject><subject>COVID-19 Serotherapy</subject><subject>COVID-19 vaccines</subject><subject>Health care</subject><subject>HEK293 Cells</subject><subject>Humans</subject><subject>Immunization, Passive</subject><subject>Infectious Diseases</subject><subject>Life Sciences</subject><subject>Medical Microbiology</subject><subject>Medical personnel</subject><subject>Membrane Glycoproteins - metabolism</subject><subject>Microbiology</subject><subject>mRNA</subject><subject>Parasitology</subject><subject>RNA viruses</subject><subject>SARS-CoV-2 - genetics</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Spike Glycoprotein, Coronavirus - genetics</subject><subject>Spike protein</subject><subject>Viral Envelope Proteins - metabolism</subject><subject>Virology</subject><issn>2058-5276</issn><issn>2058-5276</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kU1vFCEYgInR2Kb2D3gwJF68UOEdBphjndpqsqmJ3fRKYGBWmllYYeaw_vrSbv2Ih54g8PDwJg9Cbxk9Y7RRHwtnreCEAhDKaAeEvUDHQFtFWpDi5T_7I3Rayh2llAkQQonX6KhpG9FKJY9Rvgjj6LOPczATjn6Zs5nCrxA32NQzm9weZ192KRZfsJ_CEGbvsN3jPuUUza0ZKujwp-t11VvAZmNCLDO-Of9-Q_p0SwCvzNY6g0PE_Y8w-Tfo1Wim4k-f1hO0vvy87r-Q1berr_35igycdTNpOwBuKAVvnXVu5I1gdeZBNZ2krFUdSCVAGWfEOHIu20GA40Z5Z6UD25ygDwftLqefiy-z3oYy-Gky0aelaBBcSOCqYxV9_x96l5Yc63CPFAUpeVcpOFBDTqVkP-pdDluT95pR_dBEH5ro2kQ_NtEP6ndP6sVuvfvz5HeBCjQHoNSruPH579_PaO8BiLeU3Q</recordid><startdate>20220401</startdate><enddate>20220401</enddate><creator>Acevedo, Mónica L.</creator><creator>Gaete-Argel, Aracelly</creator><creator>Alonso-Palomares, Luis</creator><creator>de Oca, Marco Montes</creator><creator>Bustamante, Andrés</creator><creator>Gaggero, Aldo</creator><creator>Paredes, Fabio</creator><creator>Cortes, Claudia P.</creator><creator>Pantano, Sergio</creator><creator>Martínez-Valdebenito, Constanza</creator><creator>Angulo, Jenniffer</creator><creator>Le Corre, Nicole</creator><creator>Ferrés, Marcela</creator><creator>Navarrete, Marcelo A.</creator><creator>Valiente-Echeverría, Fernando</creator><creator>Soto-Rifo, Ricardo</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9156-2516</orcidid><orcidid>https://orcid.org/0000-0001-6435-4543</orcidid><orcidid>https://orcid.org/0000-0001-9101-9783</orcidid><orcidid>https://orcid.org/0000-0003-0945-2970</orcidid><orcidid>https://orcid.org/0000-0002-2836-9817</orcidid><orcidid>https://orcid.org/0000-0002-2044-9548</orcidid></search><sort><creationdate>20220401</creationdate><title>Differential neutralizing antibody responses elicited by CoronaVac and BNT162b2 against SARS-CoV-2 Lambda in Chile</title><author>Acevedo, Mónica L. ; Gaete-Argel, Aracelly ; Alonso-Palomares, Luis ; de Oca, Marco Montes ; Bustamante, Andrés ; Gaggero, Aldo ; Paredes, Fabio ; Cortes, Claudia P. ; Pantano, Sergio ; Martínez-Valdebenito, Constanza ; Angulo, Jenniffer ; Le Corre, Nicole ; Ferrés, Marcela ; Navarrete, Marcelo A. ; Valiente-Echeverría, Fernando ; Soto-Rifo, Ricardo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-59224a002ebdbddf4361578c839701589278628ada6ff4475c62d4a8edb7d2b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>13/1</topic><topic>13/109</topic><topic>38/22</topic><topic>38/5</topic><topic>631/326/596/4130</topic><topic>692/699/255/2514</topic><topic>ACE2</topic><topic>Angiotensin-converting enzyme 2</topic><topic>Antibodies</topic><topic>Antibodies, Neutralizing - metabolism</topic><topic>Biomedical and Life Sciences</topic><topic>BNT162 Vaccine</topic><topic>Brief Communication</topic><topic>Chile</topic><topic>Comparative analysis</topic><topic>COVID-19 - therapy</topic><topic>COVID-19 Serotherapy</topic><topic>COVID-19 vaccines</topic><topic>Health care</topic><topic>HEK293 Cells</topic><topic>Humans</topic><topic>Immunization, Passive</topic><topic>Infectious Diseases</topic><topic>Life Sciences</topic><topic>Medical Microbiology</topic><topic>Medical personnel</topic><topic>Membrane Glycoproteins - metabolism</topic><topic>Microbiology</topic><topic>mRNA</topic><topic>Parasitology</topic><topic>RNA viruses</topic><topic>SARS-CoV-2 - genetics</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Spike Glycoprotein, Coronavirus - genetics</topic><topic>Spike protein</topic><topic>Viral Envelope Proteins - metabolism</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Acevedo, Mónica L.</creatorcontrib><creatorcontrib>Gaete-Argel, Aracelly</creatorcontrib><creatorcontrib>Alonso-Palomares, Luis</creatorcontrib><creatorcontrib>de Oca, Marco Montes</creatorcontrib><creatorcontrib>Bustamante, Andrés</creatorcontrib><creatorcontrib>Gaggero, Aldo</creatorcontrib><creatorcontrib>Paredes, Fabio</creatorcontrib><creatorcontrib>Cortes, Claudia P.</creatorcontrib><creatorcontrib>Pantano, Sergio</creatorcontrib><creatorcontrib>Martínez-Valdebenito, Constanza</creatorcontrib><creatorcontrib>Angulo, Jenniffer</creatorcontrib><creatorcontrib>Le Corre, Nicole</creatorcontrib><creatorcontrib>Ferrés, Marcela</creatorcontrib><creatorcontrib>Navarrete, Marcelo A.</creatorcontrib><creatorcontrib>Valiente-Echeverría, Fernando</creatorcontrib><creatorcontrib>Soto-Rifo, Ricardo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Nature microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Acevedo, Mónica L.</au><au>Gaete-Argel, Aracelly</au><au>Alonso-Palomares, Luis</au><au>de Oca, Marco Montes</au><au>Bustamante, Andrés</au><au>Gaggero, Aldo</au><au>Paredes, Fabio</au><au>Cortes, Claudia P.</au><au>Pantano, Sergio</au><au>Martínez-Valdebenito, Constanza</au><au>Angulo, Jenniffer</au><au>Le Corre, Nicole</au><au>Ferrés, Marcela</au><au>Navarrete, Marcelo A.</au><au>Valiente-Echeverría, Fernando</au><au>Soto-Rifo, Ricardo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Differential neutralizing antibody responses elicited by CoronaVac and BNT162b2 against SARS-CoV-2 Lambda in Chile</atitle><jtitle>Nature microbiology</jtitle><stitle>Nat Microbiol</stitle><addtitle>Nat Microbiol</addtitle><date>2022-04-01</date><risdate>2022</risdate><volume>7</volume><issue>4</issue><spage>524</spage><epage>529</epage><pages>524-529</pages><issn>2058-5276</issn><eissn>2058-5276</eissn><abstract>SARS-CoV-2 variant Lambda was dominant in several South American countries, including Chile. To ascertain the efficacy of local vaccination efforts, we used pseudotyped viruses to characterize the neutralization capacity of antibodies elicited by CoronaVac (
n
= 53) and BNT162b2 (
n
= 56) in healthcare workers from Clínica Santa María and the Faculty of Medicine at Universidad de Chile, as well as in convalescent plasma from individuals infected during the first wave visiting the Hospital Clínico at Pontificia Universidad Católica (
n
= 30). We observed that BNT162b2 elicits higher neutralizing antibody titres than CoronaVac, with differences ranging from 7.4-fold for the ancestral spike (Wuhan-Hu-1) to 8.2-fold for the Lambda spike and 13-fold for the Delta spike. Compared with the ancestral virus, neutralization against D614G, Alpha, Gamma, Lambda and Delta variants was reduced by between 0.93- and 4.22-fold for CoronaVac, 1.04- and 2.38-fold for BNT162b2, and 1.26- and 2.67-fold for convalescent plasma. Comparative analyses among the spike structures of the different variants suggest that mutations in the spike protein from the Lambda variant, including the 246–252 deletion in an antigenic supersite at the N-terminal domain loop and L452Q/F490S within the receptor-binding domain, may account for immune escape. Interestingly, analyses using pseudotyped and whole viruses showed increased entry rates into HEK293T-ACE2 cells, but reduced replication rates in Vero-E6 cells for the Lambda variant when compared with the Alpha, Gamma and Delta variants. Our data show that inactivated virus and messenger RNA vaccines elicit different levels of neutralizing antibodies with different potency to neutralize SARS-CoV-2 variants, including the variant of interest Lambda.
The SARS-CoV-2 Lambda variant has been prevalent in Latin America. An analysis of the neutralization capacity of antibodies elicited by CoronaVac and BNT162b2 against SARS-CoV-2 Lambda in plasma from healthcare workers and patients in Chile reveals that BNT162b2 elicits higher neutralizing antibody titres than CoronaVac.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>35365787</pmid><doi>10.1038/s41564-022-01092-1</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0001-9156-2516</orcidid><orcidid>https://orcid.org/0000-0001-6435-4543</orcidid><orcidid>https://orcid.org/0000-0001-9101-9783</orcidid><orcidid>https://orcid.org/0000-0003-0945-2970</orcidid><orcidid>https://orcid.org/0000-0002-2836-9817</orcidid><orcidid>https://orcid.org/0000-0002-2044-9548</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2058-5276 |
| ispartof | Nature microbiology, 2022-04, Vol.7 (4), p.524-529 |
| issn | 2058-5276 2058-5276 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2646724891 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | 13/1 13/109 38/22 38/5 631/326/596/4130 692/699/255/2514 ACE2 Angiotensin-converting enzyme 2 Antibodies Antibodies, Neutralizing - metabolism Biomedical and Life Sciences BNT162 Vaccine Brief Communication Chile Comparative analysis COVID-19 - therapy COVID-19 Serotherapy COVID-19 vaccines Health care HEK293 Cells Humans Immunization, Passive Infectious Diseases Life Sciences Medical Microbiology Medical personnel Membrane Glycoproteins - metabolism Microbiology mRNA Parasitology RNA viruses SARS-CoV-2 - genetics Severe acute respiratory syndrome coronavirus 2 Spike Glycoprotein, Coronavirus - genetics Spike protein Viral Envelope Proteins - metabolism Virology |
| title | Differential neutralizing antibody responses elicited by CoronaVac and BNT162b2 against SARS-CoV-2 Lambda in Chile |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T01%3A19%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Differential%20neutralizing%20antibody%20responses%20elicited%20by%20CoronaVac%20and%20BNT162b2%20against%20SARS-CoV-2%20Lambda%20in%20Chile&rft.jtitle=Nature%20microbiology&rft.au=Acevedo,%20M%C3%B3nica%20L.&rft.date=2022-04-01&rft.volume=7&rft.issue=4&rft.spage=524&rft.epage=529&rft.pages=524-529&rft.issn=2058-5276&rft.eissn=2058-5276&rft_id=info:doi/10.1038/s41564-022-01092-1&rft_dat=%3Cproquest_cross%3E2646027749%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2646027749&rft_id=info:pmid/35365787&rfr_iscdi=true |